Characteristics of novel anticoagulants and potential economic implications.

Edith Nutescu

Journal: The American journal of managed care 2011;17(1 Suppl):S27-32

PMID: 21517653

Free Full Text on Clinical Care Targeted Communications Group, LLC View on PubMed

Abstract

Deep vein thrombosis and pulmonary embolism-the components of venous thromboembolism (VTE)-are significant causes of morbidity and mortality and are a major burden on US healthcare systems. Current VTE prevention strategies are often suboptimal after total hip or total knee arthroplasty, possibly due to drawbacks of the established anticoagulants, resulting in residual VTE and associated (or related) costs of care. New anticoagulant agents under development may address some of the limitations of current options and possibly increase adherence to guidelines for thromboprophylaxis. This article will review the characteristics of the new oral anticoagulants, which may potentially translate into cost savings for the healthcare system.

Address: Antithrombosis Center, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA. [email protected]

Link outs

Free resources

Full Text Sources:

https://www.ajmc.com/pubMed.php?pii=47739

Medical:

https://medlineplus.gov/bloodthinners.html

MeSH Terms: Anticoagulants, Benzimidazoles, Cost Savings, Dabigatran, Health Care Costs, Humans, Medication Adherence, Morpholines, Rivaroxaban, Thiophenes, United States, Venous Thromboembolism, Vitamin K, beta-Alanine